University Health Network
Blood cancer type
Role of Epigenetic Modulation in Myeloma Drug Resistance
Multiple myeloma (MM) is a B-cell tumor with survival ranging from several months to a few years. It remains incurable due to the development of a drug-resistant phenotype after prolonged therapy. Current studies focus on the targeted therapy with molecular signaling blockade by inhibitors to increase tumor septicity, reduce toxicity, and prevent drug-resistance in multiple myeloma. We propose to investigate the molecular mechanisms of epigenetic modulations in the drug resistance and evaluate lead inhibitors in MM. We will establish a model to target specific genes and overcome drug resistance in MM. Thus, our study will provide a potential novel therapeutic strategy to improve the outcome of patients with MM.